ESMO Gastrointestinal Cancers Congress | Conference

Dr Weinberg on the Rationale for Combining BXCL701 With Pembrolizumab in mPDAC

September 18th 2025

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.

Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC

September 10th 2025

Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.

Dr Élez on Health-Related QOL With Nivolumab Plus Ipilimumab in mCRC

September 2nd 2025

Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

July 7th 2025

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

July 7th 2025

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC

July 5th 2025

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC

July 5th 2025

Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC

July 5th 2025

ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.

Dr Finn on Adding Tiragolumab to Atezolizumab and Bevacizumab in Locally Advanced or Metastatic HCC

July 5th 2025

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Real-World Analysis Sheds Light on Fruquintinib Use in Later-Line Metastatic CRC

July 4th 2025

A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC

July 4th 2025

Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.

Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

July 4th 2025

Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.

Survival Benefit, Neutropenia Risk Influence Third-Line Treatment Preferences for mCRC in Germany and the UK

July 4th 2025

A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.

Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC

July 4th 2025

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC

July 4th 2025

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

Fruquintinib Demonstrates Clinical Benefit in mCRC Irrespective of Metastatic Sites at Baseline

July 4th 2025

A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.